Viewing Study NCT07227402


Ignite Creation Date: 2025-12-25 @ 3:45 AM
Ignite Modification Date: 2025-12-26 @ 2:32 AM
Study NCT ID: NCT07227402
Status: RECRUITING
Last Update Posted: 2025-12-19
First Post: 2025-11-07
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module